IBS Is a Gut-Brain Disorder. Which Therapy Ranks First?

IBS treatment should include the brain-gut axis, not because symptoms are imaginary, but because the condition involves measurable signaling between the gut and nervous system. The British Society of Gastroenterology now classifies irritable bowel syndrome as a disorder of gut-brain interaction (DGBI), replacing the older "functional gastrointestinal disorder" label. That change has a practical implication: CBT and gut-directed hypnotherapy belong alongside diet, exercise, and gut-directed treatment—not in a separate category reserved for when doctors run out of ideas.

A 2025 network meta-analysis in The Lancet Gastroenterology & Hepatology offers the most ambitious attempt yet to rank behavioral options. Its answer is useful but qualified. Minimal-contact CBT ranked first, yet every comparison in the analysis had low or very low certainty. The study gives patients several reasonable choices; it does not crown a definitive winner.

IBS is neither "all in the gut" nor "all in the head"

The DGBI framework describes conditions involving one or more of several processes: altered motility, visceral hypersensitivity, changes in mucosal or immune function, microbiota changes, and altered central nervous-system processing. The 2022 BSG guideline adopted this framework for IBS, and the Rome Working Team report defines brain-gut behavior therapies as treatments designed for these disorders.

This is a better model than treating IBS as a simple plumbing failure. Gut signals can amplify pain processing in the nervous system; attention, stress, expectation, and learned responses can in turn alter how symptoms are experienced and managed. None of that means a patient can think their way out of abdominal pain. It means the brain and gut participate in the same symptom system.

Several lines of evidence support that model. In women with IBS, a longitudinal neuroimaging and psychosocial study found that a composite neuropsychosocial signature predicted later symptom trajectories. Because the cohort included women only, it cannot establish the same predictive pattern in men. A 2025 systematic review of attention in IBS also found altered attentional biases toward visceral and pain-related threat cues, a pattern consistent with central sensitization.

The gut side of the equation remains real. A 2025 randomized trial of camostat mesilate examined microbial function in IBS and describes elevated serine-protease activity as a pathway linked to visceral hypersensitivity through PAR-2-dependent nociceptive signaling. This is mechanistic evidence, not proof that one biochemical pathway explains IBS or that a behavioral treatment replaces gut-directed care.

The Lancet ranking: promising therapies, shaky hierarchy

The Thakur et al. network meta-analysis pooled 67 randomized controlled trials with 7,441 participants. Network meta-analysis can compare treatments that were not always tested directly against each other, using a connected web of trials. That produces a P-score—a probabilistic ranking within that network—not a guarantee that the treatment with the highest score will work best for an individual patient.

Against waiting-list control at post-treatment, minimal-contact CBT ranked first: relative risk (RR) 0.55, 95% confidence interval 0.39–0.76, P-score 0.78. Telephone disease self-management followed with RR 0.57 (0.41–0.80), P-score 0.75; dynamic psychotherapy had RR 0.59 (0.43–0.80), P-score 0.72; and standard CBT had RR 0.65 (0.53–0.80), P-score 0.64. Internet-based minimal-contact CBT had RR 0.77 (0.61–0.96), P-score 0.43, while gut-directed hypnotherapy had RR 0.79 (0.66–0.95), P-score 0.39.

These estimates were statistically significant versus waiting-list control because their confidence intervals excluded 1.0. They are relative estimates, however, and the analysis does not provide an absolute probability of improvement here. A ranking also cannot tell you whether the difference between two therapies is clinically meaningful for a particular person.

Why the apparent winner should not dictate the choice

Minimal-contact CBT's first-place ranking rests on two randomized trials totaling 511 participants. Telephone self-management also rests on two trials, totaling 746 participants. Those are encouraging results, but sparse evidence can make rankings unstable.

Gut-directed hypnotherapy ranked lower but had the largest evidence base for any individual therapy in the analysis: 12 trials and 1,507 participants. Its pooled estimate still favored hypnotherapy over waiting-list control. Older studies with smaller average effects may have pulled down its pooled ranking, so a lower P-score does not establish that hypnotherapy is inferior to minimal-contact or standard CBT. The Rome Working Team classifies both IBS-specific CBT and gut-directed hypnotherapy as fully validated brain-gut behavior therapies.

The central limitation is broader than any one modality. The investigators rated every direct and indirect comparison low or very low certainty under GRADE, and no included trial had low risk of bias across every Cochrane domain. They also detected publication bias in comparisons with waiting-list control, the reference group that anchors the P-scores. Positive trials may therefore be overrepresented, making the reported effects and rankings optimistic.

Refractory IBS changes the comparison

People with symptoms that persist after prior treatment face a tougher test than patients compared with a waiting list. In the refractory subgroup, telephone disease self-management and contingency management were the only therapies that beat both attention placebo and routine care. Telephone self-management had an RR of 0.52 (0.28–0.94) versus attention placebo and 0.46 (0.31–0.69) versus routine care. Contingency management had an RR of 0.50 (0.26–0.96) versus attention placebo and 0.45 (0.24–0.85) versus routine care.

The confidence intervals against attention placebo were wide and came close to the null. Group CBT, internet-based minimal-contact disease self-management, and dynamic psychotherapy beat routine care but not attention placebo. That pattern suggests that therapeutic contact, attention, expectation, and alliance may contribute materially to outcomes in refractory IBS. It does not prove that specific behavioral techniques do nothing; it means the extra benefit of one technique over supportive contact is harder to isolate in this population.

Behavioral therapy belongs in a multimodal plan

The DGBI model does not demote food, movement, or gut-directed treatment. A 2025 network meta-analysis of dietary interventions found significant symptom reduction with low-FODMAP, gluten-free, and IBS-specific dietary approaches. A probiotic network meta-analysis found efficacy signals but could not confirm an optimal species or strain combination. A 2026 exercise network meta-analysis reported beneficial clinical outcomes across multiple exercise modalities.

Those findings support combination care, not a contest between mind and intestine. A structured dietary intervention, regular aerobic exercise, and a brain-gut behavioral therapy can address different parts of the same disorder. A clinician should also assess alarm features, alternative diagnoses, medication effects, and mental-health conditions that may affect treatment selection.

What to do with the ranking

If you can access IBS-specific CBT or gut-directed hypnotherapy, current guidelines and the trial evidence support trying one. Choose based on availability, cost, your willingness to use a digital or therapist-led format, and the skills of the provider—not on a P-score difference treated as a final verdict. A validated internet-based CBT or self-management program is a reasonable alternative when specialist care is unavailable, though current evidence has not proved it non-inferior to in-person treatment across the full range of IBS presentations.

The useful conclusion is not that IBS has become a brain disease. IBS is a disorder of brain-gut interaction, and treatment should meet it on both sides of that conversation.

For refractory symptoms, prioritize a structured program with meaningful support and set realistic expectations. The best available comparison found benefits, but it also found enough bias, imprecision, and active-control uncertainty to make certainty inappropriate. The science supports behavioral therapy as part of IBS care. It has not yet earned a single winner's trophy.